<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation and management of the adrenal incidentaloma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation and management of the adrenal incidentaloma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation and management of the adrenal incidentaloma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William F Young, Jr, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Electron Kebebew, MD, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sally E Carty, MD, FACS</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 29, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>An adrenal incidentaloma is a mass lesion greater than 1 cm in diameter, serendipitously discovered by radiologic examination [<a href="#rid1">1</a>]. This entity is the result of technological advances in imaging such as computed tomography (CT) and magnetic resonance imaging (MRI) and their widespread use in clinical practice. Discovery of an adrenal mass raises two questions that determine the degree of evaluation and the need for therapy, and both questions should be addressed simultaneously [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Is it malignant?</p><p class="bulletIndent1"><span class="glyph">●</span>Is it functioning?</p><p></p><p>The approach to the evaluation and management of adrenal incidentalomas is reviewed here. Detailed discussions of adrenal carcinoma and functioning adrenal tumors such as pheochromocytomas and aldosteronomas are found elsewhere. (See  <a class="medical medical_review" href="/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a> and  <a class="medical medical_review" href="/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma"</a> and  <a class="medical medical_review" href="/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PREVALENCE</span></p><p class="headingAnchor" id="H1332028695"><span class="h2">Unilateral masses</span><span class="headingEndMark"> — </span>Adrenal masses may be found incidentally when CT scans or MRI is done for other reasons. In a study of 61,054 abdominal CT scans performed from 1985 to 1990, an incidental adrenal tumor (incidentaloma &gt;1 cm) was detected in 259 patients (0.4 percent of all CT scans) [<a href="#rid3">3</a>]. Subsequent studies, utilizing higher-resolution scanners, have reported a prevalence of adrenal incidentaloma on abdominal CT from 1.4 to 7.3 percent [<a href="#rid4">4-6</a>]. The prevalence of adrenal incidentaloma is higher in older patients (10 percent) [<a href="#rid7">7</a>].</p><p>In autopsy studies, the prevalence of incidentalomas is 2 percent, and it ranges from 1 to 9 percent. The prevalence is higher in individuals with obesity, diabetes, and hypertension [<a href="#rid7">7</a>]. As an example, in a series of 739 autopsies, adrenal masses between 2 mm and 4 cm in size were present in 9 percent of individuals without hypertension and in 12 percent of those with hypertension [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Bilateral masses</span><span class="headingEndMark"> — </span>Analyses from two large adrenal incidentaloma studies with 887 and 202 patients showed that bilateral masses were found in 10 to 15 percent of cases [<a href="#rid9">9,10</a>]. Bilateral adrenal masses can be seen with metastatic disease, congenital adrenal hyperplasia, cortical adenomas, lymphoma, infection (eg, tuberculosis, fungal), hemorrhage, corticotropin (ACTH)-dependent Cushing syndrome, pheochromocytoma, primary aldosteronism, amyloidosis, infiltrative disease of the adrenal glands, and primary bilateral macronodular adrenal hyperplasia (PBMAH). In one study of 208 adrenal incidentaloma patients, 19 (9 percent) proved to have adrenal metastases; 10 of the 19 patients (53 percent) had bilateral disease [<a href="#rid11">11</a>].</p><p>In some patients with bilateral disease, one adrenal mass proves to be a nonfunctioning cortical adenoma, while the contralateral adrenal mass is hormone secreting [<a href="#rid10">10</a>]. In addition, adrenocortical hypofunction may occur in patients with bilateral adrenal masses. Therefore, all patients with bilateral adrenal masses should be screened for adrenocortical hyper- and hypofunction.</p><p class="headingAnchor" id="H4"><span class="h1">EVALUATION FOR MALIGNANCY</span><span class="headingEndMark"> — </span>Malignancy is an uncommon cause of adrenal incidentaloma in patients without a known diagnosis of cancer. Although estimates have varied widely, the actual frequency of primary adrenal carcinoma in patients with adrenal incidentaloma is approximately 2 to 5 percent; another 0.7 to 2.5 percent have non-adrenal metastases to the adrenal gland [<a href="#rid1">1,7,12-14</a>]. The size and imaging characteristics ("imaging phenotype") of the mass may help determine whether the tumor is benign or malignant [<a href="#rid1">1,13,15</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Size</span><span class="headingEndMark"> — </span>The maximum diameter of the adrenal mass is predictive of malignancy [<a href="#rid16">16</a>]. This was illustrated in a study of 887 patients with adrenal incidentalomas from the National Italian Study Group on Adrenal Tumors [<a href="#rid9">9</a>]. Adrenocortical carcinomas were significantly associated with mass size, with 90 percent being more than 4 cm in diameter when discovered.</p><p>Adrenal mass size is also important because the smaller the adrenocortical carcinoma is at the time of diagnosis, the better the overall prognosis. In a retrospective review of 62 patients with adrenocortical carcinoma, five-year survival was approximately 16 percent overall, but much higher (42 percent) in patients with smaller tumors (stages I and II, confined to the adrenal gland) who were more likely to undergo curative resection [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a> and  <a class="medical medical_review" href="/d/html/165.html" rel="external">"Treatment of adrenocortical carcinoma"</a>.)</p><p>In the report from the National Italian Study Group, a 4 cm cutoff had a 93 percent sensitivity of detecting adrenocortical carcinoma, even though specificity was limited (76 percent of masses larger than 4 cm in diameter were benign) [<a href="#rid9">9,13</a>]. In the Mayo Clinic study cited above, all 20 adrenal carcinomas were between 4 and 6 cm in diameter [<a href="#rid3">3</a>]. Therefore, surgical removal of unilateral adrenal masses larger than 4 cm should be considered to avoid missing adrenal carcinomas, particularly in younger patients. (See <a class="local">'Management'</a> below.)</p><p>However, adrenal mass size should not be used as the only parameter to guide treatment. In a retrospective, single-center cohort of 4085 patients with adrenal tumors, 705 (17 percent) had adrenal masses measuring 4 cm or more in diameter; of these, 216 (31 percent) were adrenocortical adenomas, 158 (22 percent) were pheochromocytomas, 116 (16 percent) were other benign adrenal tumors, 88 (13 percent) were adrenocortical carcinomas, and 127 (18 percent) were other malignant tumors [<a href="#rid18">18</a>]. On multivariate analysis, older age at diagnosis, male sex, nonincidental mode of discovery, larger tumor size, and higher unenhanced CT attenuation were all found to be statistically significant predictors of malignancy [<a href="#rid18">18</a>]. (See <a class="local">'Imaging phenotype'</a> below and <a class="local">'Monitoring when surgery not performed'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h2">Imaging phenotype</span><span class="headingEndMark"> — </span>CT or MRI with 2 to 3 mm cuts may allow prediction of the histologic type of the adrenal tumor [<a href="#rid1">1,9</a>]. As an example, the lipid-rich nature of a cortical adenoma is helpful in distinguishing this benign tumor from carcinoma  (<a class="graphic graphic_diagnosticimage graphicRef52211" href="/d/graphic/52211.html" rel="external">image 1</a>).</p><p class="headingAnchor" id="H7"><span class="h3">CT scan</span></p><p class="headingAnchor" id="H446737221"><span class="h4">Unenhanced attenuation</span><span class="headingEndMark"> — </span>On CT scanning, the density of the image (black is less dense) is attributed to radiograph attenuation. The intracytoplasmic fat in adenomas results in low attenuation on unenhanced CT; non-adenomas have higher attenuation in unenhanced CT. The Hounsfield scale is a semiquantitative method of measuring radiograph attenuation. Typical precontrast Hounsfield unit (HU) values are for adipose tissue (-20 to -150 HU) and kidney (20 to 150 HU). If an adrenal mass measures &lt;10 HU on unenhanced CT (ie, has the density of fat), the likelihood that it is a benign adenoma is nearly 100 percent. However, up to 30 percent of adenomas do not contain large amounts of lipid and may be indistinguishable from non-adenomas on nonenhanced CT scans and are termed <strong>lipid-poor</strong> adenomas. Although imaging phenotype does not predict hormonal function, it does predict underlying pathology, and surgical resection should be considered in patients with adrenal incidentalomas that have a suspicious imaging phenotype [<a href="#rid1">1</a>]. (See <a class="local">'Typical imaging features'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>HU&lt;10</strong> – A consensus panel noted that a homogeneous adrenal mass with a smooth border and an attenuation value &lt;10 HU on unenhanced CT is very likely to be a benign adenoma [<a href="#rid2">2</a>]. This appears to be a reasonable CT HU cutoff based upon a retrospective analysis of 151 patients with adrenal masses who underwent both a noncontrast CT scan and adrenalectomy [<a href="#rid19">19</a>]. The mean HU (± standard deviation [SD]) for adrenal adenomas/hyperplasia was significantly lower than for adrenal carcinomas, metastases, and pheochromocytomas (16.2±13.6 versus 36.9±4.1, 39.2±15.2, and 38.6±8.2, respectively). The only patients in the nonadenoma groups with a noncontrast CT HU &lt;10 were those with myelolipomas (which were all less than -40 and therefore easily distinguishable). In this series, an unenhanced CT attenuation ≤10 HU or a combination of tumor size ≤4 cm and HU ≤20 excluded non-adenomas in 100 percent of cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HU&gt;10</strong> – In a retrospective cohort study of 353 patients with adrenal nodules who underwent adrenal biopsy and/or adrenalectomy, 80 percent of patients presented with known or suspected extra-adrenal malignancy [<a href="#rid20">20</a>]. Adrenal masses with unenhanced CT attenuation &gt;10 HU diagnosed malignancy with a sensitivity of 100 percent, specificity of 33 percent, positive predictive value (PPV) of 72 percent, and negative predictive value (NPV) of 100 percent. Unenhanced CT attenuation of ≤10 HU excluded malignancy even in this high-risk population.</p><p></p><p class="headingAnchor" id="H2527280304"><span class="h4">Delayed contrast-enhanced CT</span><span class="headingEndMark"> — </span>Initial studies suggested that on delayed contrast-enhanced CT, the rapidity of contrast medium washout could distinguish between adrenal adenoma and non-adenomas [<a href="#rid21">21</a>]. Ten minutes after administration of contrast, an absolute contrast medium washout of more than 50 percent was reported to be 100 percent sensitive and specific for adenoma when patients with adenomas were compared with those with carcinomas, pheochromocytomas, and metastases [<a href="#rid22">22,23</a>]. However, contrast medium washout may have limited utility for excluding malignancy and pheochromocytoma in indeterminate, lipid-poor nodules. One retrospective study of adrenal nodules with an attenuation value of &gt;10 HU found that contrast washout greater than 60 percent had substantially lower sensitivity (77.5 percent) and specificity (70 percent) for benign adenoma in adrenal masses &lt;4 cm [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H8"><span class="h3">MRI</span><span class="headingEndMark"> — </span>Although CT is the recommended primary adrenal imaging procedure in most cases, MRI has advantages in certain clinical situations. For example, follow-up imaging with MRI avoids the radiation exposure of repeated CT imaging.</p><p class="bulletIndent1"><span class="glyph">●</span>Conventional spin-echo MRI is the most frequently used technique. Using low or mid-field-strength magnets, T1- and T2-weighted imaging can distinguish benign adenomas from malignancy and pheochromocytoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MR with chemical shift imaging (CSI) accurately distinguishes adrenal adenomas from non-adenomas based on their elevated amounts of intracytoplasmic fat [<a href="#rid25">25</a>]. In a meta-analysis of 1280 lesions (859 adenomas), CSI demonstrated a sensitivity of 94 percent (95% CI 88-97 percent) and a specificity of 95 percent (95% CI 89-97 percent). No difference in diagnostic performance was seen when quantitative versus qualitative image analysis was compared.</p><p></p><p class="headingAnchor" id="H9"><span class="h3">Other</span><span class="headingEndMark"> — </span>Positron emission tomography (PET) with either fludeoxyglucose F 18 (FDG) [<a href="#rid26">26,27</a>] or 11C-metomidate (MTO) [<a href="#rid28">28</a>] can be helpful in selected patients (eg, those with a prior history of malignancy or those in which unenhanced CT attenuation or washout analysis is inconclusive or suspicious for malignancy [<a href="#rid7">7</a>]) because of their high sensitivity for detecting malignancy [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors", section on 'Radiographic studies'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Typical imaging features</span><span class="headingEndMark"> — </span>The imaging characteristics of adrenal masses are summarized here.</p><p class="headingAnchor" id="H11"><span class="h3">Benign adenomas</span></p><p class="bulletIndent1"><span class="glyph">●</span>Round and homogeneous density, smooth contour, and sharp margination [<a href="#rid29">29</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diameter less than 4 cm, unilateral location</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low unenhanced CT attenuation values (≤10 HU)  (<a class="graphic graphic_diagnosticimage graphicRef52211" href="/d/graphic/52211.html" rel="external">image 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isointensity with liver on both T1- and T2-weighted MRI sequences</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chemical shift evidence of lipid on MRI</p><p></p><p class="headingAnchor" id="H12"><span class="h3">Pheochromocytomas</span></p><p class="bulletIndent1"><span class="glyph">●</span>Increased attenuation on unenhanced CT (&gt;20 HU) [<a href="#rid30">30</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased mass vascularity  (<a class="graphic graphic_diagnosticimage graphicRef52609" href="/d/graphic/52609.html" rel="external">image 2</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High signal intensity on T2-weighted MRI  (<a class="graphic graphic_diagnosticimage graphicRef75766" href="/d/graphic/75766.html" rel="external">image 3</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cystic and hemorrhagic changes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Variable size and may be bilateral</p><p></p><p class="headingAnchor" id="H13"><span class="h3">Adrenocortical carcinoma</span></p><p class="bulletIndent1"><span class="glyph">●</span>Irregular shape</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhomogeneous density because of central areas of low attenuation due to tumor necrosis  (<a class="graphic graphic_diagnosticimage graphicRef53633" href="/d/graphic/53633.html" rel="external">image 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor calcification</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diameter usually &gt;4 cm</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral location</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High unenhanced CT attenuation values (&gt;20 HU)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhomogeneous enhancement on CT with intravenous contrast</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypointensity compared with liver on T1-weighted MRI and high to intermediate signal intensity on T2-weighted MRI</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High standardized uptake value (SUV) on FDG-PET-CT study</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of local invasion or metastases (see  <a class="medical medical_review" href="/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors", section on 'Radiographic studies'</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h3">Adrenal metastases</span></p><p class="bulletIndent1"><span class="glyph">●</span>Irregular shape and inhomogeneous nature  (<a class="graphic graphic_diagnosticimage graphicRef126149" href="/d/graphic/126149.html" rel="external">image 5</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tendency to be bilateral</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High unenhanced CT attenuation values (&gt;20 HU) and enhancement with intravenous contrast on CT</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isointensity or slightly less intense than the liver on T1-weighted MRI and high to intermediate signal intensity on T2-weighted MRI (representing an increased water content)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated SUV on FDG-PET scan</p><p></p><p class="headingAnchor" id="H15"><span class="h3">Other</span><span class="headingEndMark"> — </span>Adrenal cysts, adrenal hemorrhage, and myelolipoma  (<a class="graphic graphic_diagnosticimage graphicRef72437" href="/d/graphic/72437.html" rel="external">image 6</a>) are usually easily characterized because of their distinctive imaging characteristics.</p><p class="headingAnchor" id="H16"><span class="h2">Fine-needle aspiration biopsy</span><span class="headingEndMark"> — </span>Cytology from a specimen obtained by fine-needle aspiration (FNA) biopsy <strong>cannot</strong> distinguish a benign cortical adrenal mass from the less common adrenal carcinoma. It can, however, distinguish between an adrenal tumor and a metastatic tumor [<a href="#rid31">31</a>]. In a patient with a known primary malignancy elsewhere who has a newly discovered adrenal mass that has an imaging phenotype consistent with metastatic disease, performing a diagnostic CT-guided FNA biopsy may be indicated, but only after excluding pheochromocytoma with biochemical testing. Adrenal biopsy would not be needed if the patient was already known to have widespread metastatic disease [<a href="#rid32">32,33</a>].</p><p>One report, as an example, evaluated patients with known lung cancer and an adrenal mass; FNA biopsy revealed a benign adrenal lesion in two-thirds of cases [<a href="#rid29">29</a>]. When the non-adrenal cancer is occult, most adrenal masses are incidentaloma cortical adenomas (91 of 95 in one study [<a href="#rid34">34</a>]). Thus, FNA biopsy is not useful in the routine evaluation of incidentalomas in patients suspected to have small non-adrenal cancers.</p><p>Image-guided FNA biopsy is relatively safe; the complication rate was 2.8 percent in one series of 277 biopsies [<a href="#rid35">35</a>]. The risks of this procedure include adrenal and liver hematoma, abdominal pain, hematuria, pancreatitis, pneumothorax, formation of an adrenal abscess, and tumor recurrence along the needle track [<a href="#rid35">35,36</a>]. The FNA biopsy of a pheochromocytoma may result in hemorrhage and hypertensive crisis [<a href="#rid37">37</a>]. Therefore, the possibility of pheochromocytoma should always be ruled out by biochemical testing before FNA biopsy is undertaken [<a href="#rid37">37-39</a>].</p><p class="headingAnchor" id="H17"><span class="h1">EVALUATION FOR HORMONAL SECRETION</span><span class="headingEndMark"> — </span>While most adrenal incidentalomas are nonfunctional, 10 to 15 percent secrete excess amounts of hormones [<a href="#rid13">13,14</a>]. The most complete analysis of this issue comes from a review of all 828 published articles on adrenal incidentalomas from 1980 to 2008 [<a href="#rid14">14</a>]. Only 20 of the 828 articles were selected as having met the strict criteria for a "true" adrenal incidentaloma; of these, only nine had adequate data on both diagnosis and follow-up. Patients who were suspected as having cancer were excluded. Among the 1800 patients in these nine series, these overall mean percentages of diagnoses were reported:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignant</strong> – Primary adrenal carcinoma 1.9 percent, metastases 0.7 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign</strong> – Nonfunctioning 89.7 percent, subclinical Cushing syndrome 6.4 percent, pheochromocytoma 3.1 percent, primary aldosteronism 0.6 percent</p><p></p><p>Three forms of adrenal hyperfunction should be considered in<strong> </strong>all patients who are diagnosed with an adrenal incidentaloma  (<a class="graphic graphic_algorithm graphicRef126129" data-inline-graphics="126129" href="/d/graphic/126129.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Subclinical glucocorticoid secretory autonomy (subclinical Cushing syndrome), assuming that another diagnosis (eg, pheochromocytoma) is <strong>not</strong> present</p><p class="bulletIndent1"><span class="glyph">●</span>Pheochromocytoma if the unenhanced CT attenuation is &gt;10 HU</p><p class="bulletIndent1"><span class="glyph">●</span>Primary aldosteronism if the patient is hypertensive or has hypokalemia</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Subclinical Cushing syndrome</span><span class="headingEndMark"> — </span>Subclinical Cushing syndrome (or mild autonomous cortisol secretion [MACS], cortisol hypersecretion without clinical manifestations of Cushing syndrome) is the most frequent hormonal abnormality detected in patients with adrenal incidentalomas. Some adrenal incidentalomas secrete cortisol independently of corticotropin (ACTH) [<a href="#rid40">40</a>], which may have clinically important consequences [<a href="#rid41">41</a>]. Cortisol secretion can be under the control of one or more aberrant hormone receptors in patients with unilateral adenomas or incidental primary bilateral macronodular adrenal hyperplasia (PBMAH) [<a href="#rid42">42,43</a>]. (See  <a class="medical medical_review" href="/d/html/148.html" rel="external">"Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia", section on 'Aberrant hormone receptors'</a>.)</p><p class="headingAnchor" id="H19"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>Although these patients lack many of the usual stigmata of overt Cushing syndrome, they may have one or more of the effects of continuous ACTH-independent cortisol secretion, including hypertension, dyslipidemia, diabetes, weight gain, osteoporosis, and evidence of atherosclerosis [<a href="#rid41">41,44-46</a>].</p><p>In a meta-analysis of 47 observational studies in 17,156 participants with adrenal incidentaloma, individuals with MACS (defined as serum cortisol &gt;1.8 mcg/dL after a 1 mg overnight <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test) exhibited a higher prevalence of diabetes (20 studies; relative risk [RR] 1.44, 95% CI 1.23-1.69), hypertension (31 studies; RR 1.24, 95% CI 1.16-1.32), and dyslipidemia (22 studies; RR 1.23, 95% CI 1.13-1.34) compared with participants with nonfunctioning adrenal adenomas [<a href="#rid47">47</a>]. In 10 studies that reported fracture data, study design and findings were heterogeneous; nonetheless, two cohort studies identified higher incidence of vertebral fractures or all clinical fractures in individuals with MACS compared with those with nonfunctioning adenomas [<a href="#rid48">48,49</a>]. For example, in a two-year longitudinal study of 103 consecutive patients with adrenal incidentaloma, the incidence of new vertebral fractures was higher in patients with MACS (48 percent) than in those without MACS (13 percent) [<a href="#rid48">48</a>]. </p><p>Atrial fibrillation (AF) is more common in patients with MACS when compared with those with nonsecreting adenomas. In a retrospective study of patients with MACS or nonsecreting adenomas (n = 632), the prevalence of AF was higher at baseline in the ACS patients (8.5 percent, 18 of 212) compared with the nonsecreting group (3.1 percent, 13 of 420) [<a href="#rid50">50</a>]. At the completion of the study (median follow-up of 7.7 years), the AF rate remained higher in the MACS group: 20 percent (22 of 108) versus the nonsecreting group, 12 percent (30 of 249). Given these rates, patients with MACS should be monitored for AF.</p><p class="headingAnchor" id="H20"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>Subclinical Cushing syndrome should be ruled out by obtaining a baseline serum dehydroepiandrosterone sulfate (DHEAS) and performing the 1 mg overnight <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test (DST)  (<a class="graphic graphic_algorithm graphicRef126129" href="/d/graphic/126129.html" rel="external">algorithm 1</a>) [<a href="#rid51">51</a>]. Of note, the overnight DST should <strong>not </strong>be performed if the patient is thought to have a pheochromocytoma based upon the initial imaging study (unenhanced CT attenuation &gt;10 HU). Reports of catecholaminergic crisis (some fatal) during DSTs have been described in patients with pheochromocytoma. Although most have been with high-dose DST, cases with low-dose DST have also been described [<a href="#rid52">52,53</a>].</p><p>Random, morning, or late-night serum cortisol levels are not useful for diagnosis of subclinical Cushing syndrome. In addition, most ACTH assays lack sensitivity at the lower part of the reference range and cannot be relied on to identify autonomous cortisol secretion.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>DHEAS</strong> – A low DHEAS reflects chronic suppression of ACTH secretion. In a study of 185 patients with adrenal incidentaloma, 29 patients (16 percent) were diagnosed with subclinical Cushing syndrome [<a href="#rid54">54</a>]. An age- and sex-specific DHEAS ratio (derived by dividing the DHEAS by the lower limit of the respective reference range for age and sex) of &lt;1.12 was sensitive (&gt;99 percent) and specific (91.9 percent) for the diagnosis of subclinical Cushing syndrome [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1">In a retrospective study of 256 patients with adrenal incidentaloma and MACS, a serum DHEAS concentration &lt;40 mcg/dL was 84 percent specific for MACS, whereas an ACTH concentration &lt;10 pg/mL was only 75 percent specific for MACS [<a href="#rid55">55</a>]. In addition, a serum DHEAS concentration &gt;100 mcg/dL combined with an ACTH concentration &gt;15 pg/mL was 96 percent specific for excluding MACS [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DST</strong> – An abnormal 1 mg overnight DST (cortisol &gt;1.8 mcg/dL [&gt;50 nmol/L]) is consistent with ACTH-independent autonomous cortisol production. Some centers use a higher dose of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (eg, 3 mg rather than the standard 1 mg) to reduce false-positive results [<a href="#rid56">56</a>]. Positive findings on the initial DST should be further evaluated with 24-hour urinary free cortisol, serum ACTH concentration, and a high-dose (8 mg) overnight DST. <strong>Clinically significant</strong> glucocorticoid secretory autonomy is confirmed by a post-overnight 8 mg DST 8 AM serum cortisol concentration &gt;1.8 mcg/dL (&gt;50 nmol/L). (See  <a class="medical medical_review" href="/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a>.)</p><p></p><p class="bulletIndent1">A study of the two-day, low-dose DST [<a href="#rid57">57</a>] showed a gradation between subnormal and complete suppression of serum cortisol concentrations in 57 patients with adrenal incidentalomas (21 percent had undetectable serum levels of cortisol, 67 percent had values between 1 and 5 mcg/dL, and 12 percent had values between 5.0 and 7.8 mcg/dL). Thus, the question for the clinician when glucocorticoid secretory activity is found is whether the cortical adenoma has <strong>clinically significant</strong> glucocorticoid secretory activity.</p><p></p><p class="headingAnchor" id="H3926050602"><span class="h3">Bilateral adrenal masses and subclinical Cushing syndrome</span><span class="headingEndMark"> — </span>This clinical scenario is being increasingly recognized. When the bilateral adrenal masses are consistent with solitary bilateral adenomas on cross-sectional computed imaging, consideration should be given to adrenal venous sampling [<a href="#rid58">58-60</a>] (see  <a class="medical medical_review" href="/d/html/138.html" rel="external">"Diagnosis of primary aldosteronism", section on 'Adrenal vein sampling'</a>). In this setting, adrenal venous sampling is performed without cosyntropin administration, and successful adrenal vein catheterization is confirmed with either catecholamine or metanephrine gradients between the adrenal veins and the inferior vena cava [<a href="#rid60">60</a>].</p><p>In a study of 14 patients with bilateral adrenal nodules and ACTH-independent subclinical or clinical Cushing syndrome, 10 had bilateral and 4 had unilateral cortisol overproduction [<a href="#rid59">59</a>]. In patients where the computed images of the primary adrenal glands are consistent with PBMAH  (<a class="graphic graphic_diagnosticimage graphicRef126150" href="/d/graphic/126150.html" rel="external">image 7</a>), adrenal vein sampling is <strong>not</strong> needed, because this is a bilateral adrenal disorder. (See  <a class="medical medical_review" href="/d/html/148.html" rel="external">"Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia", section on 'Initial evaluation'</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Pheochromocytoma</span><span class="headingEndMark"> — </span>Approximately 3 percent of adrenal incidentalomas prove to be pheochromocytomas [<a href="#rid14">14</a>]. In the past, it was thought that all patients with pheochromocytoma are symptomatic. However, with widespread use of computed imaging, pheochromocytomas are being discovered in the presymptomatic stage [<a href="#rid61">61,62</a>]. In a study of 271 consecutive patients with pheochromocytoma treated from 2005 to 2016, 61 percent were discovered as an incidental finding on cross-section imaging, 27 percent due to pheochromocytoma-related symptoms, and 12 percent due to mutation-based testing [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma", section on 'Approach to initial evaluation'</a>.)</p><p>Biochemical testing for pheochromocytoma should be performed if the unenhanced CT attenuation is ≥10 HU, but not if it is &lt;10 HU  (<a class="graphic graphic_algorithm graphicRef126129" href="/d/graphic/126129.html" rel="external">algorithm 1</a>) [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma", section on 'Imaging'</a>.)</p><p>Small pheochromocytomas (eg, &lt;1.5 cm) may have normal biochemical testing  (<a class="graphic graphic_diagnosticimage graphicRef126151" href="/d/graphic/126151.html" rel="external">image 8</a>). Pheochromocytomas need a critical mass before they can become biochemically detectable. Surgical resection of apparent nonfunctioning lipid-poor and vascular adrenal masses should be considered  (<a class="graphic graphic_algorithm graphicRef126129" href="/d/graphic/126129.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H22"><span class="h2">Aldosteronomas</span><span class="headingEndMark"> — </span>Aldosteronomas are rare (less than 1 percent) causes of an adrenal incidentaloma. However, because the majority of patients with primary aldosteronism are not hypokalemic, all patients with hypertension and an adrenal incidentaloma should be evaluated by measurements of plasma aldosterone concentration and plasma renin activity [<a href="#rid1">1,2</a>]. In addition, patients who are normotensive but have spontaneous hypokalemia should also be tested for primary aldosteronism  (<a class="graphic graphic_algorithm graphicRef126129" href="/d/graphic/126129.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/138.html" rel="external">"Diagnosis of primary aldosteronism"</a> and  <a class="medical medical_review" href="/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism"</a>.)</p><p class="headingAnchor" id="H2712678581"><span class="h2">Confirmatory testing</span><span class="headingEndMark"> — </span>The diagnosis and confirmation of clinically important subclinical Cushing syndrome is described above (see <a class="local">'Subclinical Cushing syndrome'</a> above). If there is biochemical evidence of either a pheochromocytoma or aldosterone-secreting adenoma on initial testing, confirmatory testing is required before treatment is considered. Confirmatory testing for these disorders is described elsewhere. (See  <a class="medical medical_review" href="/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma", section on 'Indeterminate case-detection test'</a> and  <a class="medical medical_review" href="/d/html/138.html" rel="external">"Diagnosis of primary aldosteronism", section on 'Confirmation of the diagnosis'</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Our approach to management is largely consistent with guidelines from the American Association of Endocrine Surgeons [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H24"><span class="h2">Unilateral adrenal masses</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pheochromocytoma and adrenocortical cancer</strong> – All patients with documented pheochromocytoma and adrenocortical cancer should undergo prompt surgical intervention because untreated pheochromocytoma may result in significant cardiovascular complications. Alpha-adrenergic blockade should be given before patients undergo adrenalectomy. (See  <a class="medical medical_review" href="/d/html/142.html" rel="external">"Treatment of pheochromocytoma in adults"</a>.)</p><p></p><p class="bulletIndent1">Patients with adrenocortical cancer or lesions suspicious for adrenocortical cancer should also undergo prompt adrenalectomy as their disease may progress rapidly. (See  <a class="medical medical_review" href="/d/html/165.html" rel="external">"Treatment of adrenocortical carcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aldosterone-producing adenomas</strong> – Patients with aldosterone-producing adenomas should be offered surgery to cure aldosterone excess. (See  <a class="medical medical_review" href="/d/html/141.html" rel="external">"Treatment of primary aldosteronism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subclinical Cushing syndrome</strong> – Should all patients with this diagnosis undergo unilateral adrenalectomy? In the absence of a prospective, randomized study, it is reasonable to consider younger patients as candidates for adrenalectomy. Patients who have disorders potentially attributable to autonomous glucocorticoid secretion (eg, recent onset of hypertension, diabetes, obesity, and/or low bone mass) with well-documented glucocorticoid secretory autonomy (ie, suppressed dehydroepiandrosterone sulfate [DHEAS], failure to suppress cortisol normally on 1 mg overnight <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> test [DST], low serum corticotropin [ACTH] concentration, lack of suppression to high-dose overnight DST [8 AM serum cortisol &gt;1.8 mcg/dL]) are also candidates for adrenalectomy.</p><p></p><p class="bulletIndent1">In a meta-analysis of 47 studies in participants with adrenal incidentaloma, participants with subclinical Cushing syndrome who underwent adrenalectomy showed greater improvement in cardiometabolic parameters compared with those who did not undergo surgery (11 studies) [<a href="#rid47">47</a>]; however, these data were predominantly observational.</p><p></p><p class="bulletIndent1">If adrenalectomy is performed, a postoperative <a class="drug drug_general" data-topicid="9298" href="/d/drug information/9298.html" rel="external">ACTH stimulation test</a> should be done to confirm adequate adrenocortical function. If this test is not performed or demonstrates inadequate adrenocortical function, perioperative glucocorticoid coverage should be administered because of the risk of adrenal insufficiency, hemodynamic crisis, and death. Patients should be sent home from the hospital on glucocorticoid replacement and monitored for recovery of the hypothalamic-pituitary-adrenal axis [<a href="#rid65">65</a>]. Weight loss, improvement in hypertension and/or glycemic management, and normalization of markers of bone turnover are frequently found following unilateral adrenalectomy in patients with subclinical Cushing syndrome [<a href="#rid66">66-68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipid-poor adrenal masses</strong> – Adrenal masses with either suspicious imaging phenotype or size larger than 4 cm should be considered for resection because a substantial fraction will be adrenocortical carcinomas [<a href="#rid2">2,17</a>]. The clinical scenario and patient age frequently guide the management decisions in patients who have adrenal incidentalomas that fall on either side of the 4 cm diameter cutoff. As an example, most clinicians would advise resecting a lipid-poor (29 HU) 3.2 cm adrenal incidentaloma in a 23-year-old woman, whereas most clinicians would choose serial imaging follow-up in an 83-year-old woman with a lipid-rich (9 HU) 4.7 cm adrenal incidentaloma. Before surgery, all patients should undergo appropriate testing for functional tumors. (See <a class="local">'Evaluation for hormonal secretion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenal myelolipoma</strong> – This is a benign tumor composed of mature fat and interspersed hematopoietic elements that resemble bone marrow. On computed imaging, the presence of large amounts of macroscopic fat in an adrenal mass is diagnostic of a myelolipoma  (<a class="graphic graphic_diagnosticimage graphicRef72437" href="/d/graphic/72437.html" rel="external">image 6</a>) [<a href="#rid69">69</a>]. Although adrenal myelolipomas may grow over time, they can usually be followed without surgical excision. However, when larger than 6 cm in diameter or when causing local mass-effect symptoms, surgical removal should be considered. When adrenal myelolipomas are bilateral, the clinician should consider the diagnosis of congenital adrenal hyperplasia [<a href="#rid70">70</a>].</p><p></p><p class="headingAnchor" id="H25"><span class="h2">Bilateral adrenal masses</span><span class="headingEndMark"> — </span>The management of bilateral adrenal masses is different from that for unilateral masses. As an example, in cases of primary bilateral macronodular adrenal hyperplasia (PBMAH)  (<a class="graphic graphic_diagnosticimage graphicRef126150" href="/d/graphic/126150.html" rel="external">image 7</a>), size is not an indication for surgery, whereas the degree of cortisol secretory autonomy should guide surgical decision-making. Patients with PBMAH and clinical Cushing syndrome usually are best treated with bilateral adrenalectomy, whereas patients with PBMAH and subclinical Cushing syndrome may be managed by resecting the larger adrenal gland.</p><p>Surgical management should be guided by the findings on adrenal venous sampling in patients with ACTH-independent Cushing syndrome or subclinical Cushing syndrome in the setting of solitary bilateral adrenal adenomas [<a href="#rid58">58-60</a>].</p><p class="headingAnchor" id="H26"><span class="h2">Adrenalectomy</span><span class="headingEndMark"> — </span>Adrenalectomy for patients with aldosteronomas, pheochromocytoma, cortisol-secreting tumors, and adrenal incidentalomas is safe and effective [<a href="#rid71">71</a>]. An adrenalectomy may be done laparoscopically, endoscopically via the posterior approach, or as an open procedure. Laparoscopic adrenalectomy, compared with open adrenalectomy, is associated with less pain, shorter hospitalization time, less blood loss, and faster recovery [<a href="#rid72">72</a>]. The laparoscopic approach is used for most adrenal masses [<a href="#rid64">64</a>].</p><p>In patients with known or suspected adrenal carcinoma, the laparoscopic approach should only be considered if the adrenal mass is &lt;10 cm and does not appear to be locally invasive [<a href="#rid73">73,74</a>]. An open adrenalectomy is recommended for all large (&gt;10 cm) adrenal masses, including those benign imaging features, as the adrenal mass may be diagnosed as malignant on a definitive histologic review [<a href="#rid73">73,75-78</a>]. (See <a class="local">'Imaging phenotype'</a> above and  <a class="medical medical_review" href="/d/html/15027.html" rel="external">"Adrenalectomy techniques", section on 'Approach by indication'</a>.)</p><p class="headingAnchor" id="H27"><span class="h2">Monitoring when surgery not performed</span><span class="headingEndMark"> — </span>For incidentalomas with a benign appearance on imaging, repeat imaging after 12 months should be performed to reconfirm the initial diagnosis of a benign adrenal mass [<a href="#rid7">7</a>]. The decision to obtain additional images (eg, at 3, 6, 12, and 24 months after the initial image) and the type of image obtained (eg, CT or MRI) should be guided by the individual clinical circumstance, imaging phenotype, and clinical judgment  (<a class="graphic graphic_algorithm graphicRef126129" href="/d/graphic/126129.html" rel="external">algorithm 1</a>).</p><p>As an example, a single repeat image is reasonable in patients who have no history of malignancy and who have small (less than 2 cm), uniform, low unenhanced CT attenuation cortical nodules (ie, benign imaging phenotype). There are no prospective studies of the optimal frequency and duration of follow-up for adrenal incidentalomas. In addition, the radiation exposure related to CT should be considered [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/14613.html" rel="external">"Radiation-related risks of imaging", section on 'Clinical decision-making and informing patients'</a>.)</p><p>Most experts would consider resecting any tumor that enlarges by more than 1 cm in diameter during the follow-up period  (<a class="graphic graphic_algorithm graphicRef126129" href="/d/graphic/126129.html" rel="external">algorithm 1</a>). However, most adrenal masses that grow are not malignant. Nonetheless, surgical removal should be considered for masses ≥4 cm to avoid missing adrenal carcinomas, particularly in younger patients. (See <a class="local">'Size'</a> above.)</p><p>The observation that autonomous function (glucocorticoid hypersecretion) not present at baseline may be detected at follow-up testing [<a href="#rid79">79-81</a>] has led to the recommendation for repeating the baseline DHEAS measurement and the overnight DST annually for four years in cases where initial evaluation is negative [<a href="#rid1">1,80,81</a>]; however, the yield and cost effectiveness of such testing is also unknown [<a href="#rid7">7,14</a>].</p><p class="headingAnchor" id="H3293775804"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112709.html" rel="external">"Society guideline links: Diagnosis and treatment of Cushing syndrome"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112785.html" rel="external">"Society guideline links: Adrenal incidentaloma"</a>.)</p><p class="headingAnchor" id="H33148939"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83148.html" rel="external">"Patient education: Adrenal cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenal incidentaloma</strong> <strong>definition</strong> – An adrenal incidentaloma is a mass lesion greater than 1 cm in diameter, serendipitously discovered by radiologic examination. This entity is the result of technological advances in imaging such as CT and MRI. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging phenotype</strong> – All patients with adrenal incidentalomas should be evaluated for the possibility of malignancy. The size and imaging characteristics ("imaging phenotype") of the mass may help determine whether the tumor is benign or malignant. (See <a class="local">'Evaluation for malignancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Benign cortical adenoma</strong> – A homogeneous adrenal mass &lt;4 cm in diameter, with a smooth border, and an attenuation value &lt;10 Hounsfield unit (HU) on unenhanced CT is very likely to be a benign cortical adenoma. (See <a class="local">'CT scan'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adrenal carcinoma or metastases</strong> – The imaging characteristics that suggest adrenal carcinoma or metastases include irregular shape, inhomogeneous density, high unenhanced CT attenuation values (&gt;20 HU), diameter &gt;4 cm, and tumor calcification. Other characteristics are described above. (See <a class="local">'Adrenocortical carcinoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation for hormonal secretion</strong> – All patients with adrenal incidentalomas should be evaluated for the possibility of subclinical hormonal hyperfunction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pheochromocytoma</strong> – Pheochromocytoma should be excluded in all patients with adrenal incidentalomas with unenhanced CT attenuation &gt;10 HU by measuring 24-hour urinary fractionated metanephrines and catecholamines or plasma fractionated metanephrines. (See <a class="local">'Pheochromocytoma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subclinical Cushing syndrome</strong> – Subclinical Cushing syndrome should be ruled out by measuring baseline dehydroepiandrosterone sulfate (DHEAS) and performing the 1 mg overnight <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test (DST). To detect <strong>clinically significant</strong> glucocorticoid secretory autonomy, the post-overnight 1 mg DST 8 AM serum cortisol concentration cutoff is &gt;1.8 mcg/dL (&gt;50 nmol/L). An abnormal 1 mg overnight DST is consistent with corticotropin (ACTH)-independent cortisol production, a finding that should be confirmed with 24-hour urinary free cortisol, serum ACTH concentration, and a high-dose (8 mg) overnight DST. (See <a class="local">'Subclinical Cushing syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary aldosteronism (selected patients)</strong> – If the adrenal incidentaloma patient has hypertension or hypokalemia, a plasma aldosterone level and plasma renin activity should be measured to screen for primary aldosteronism. (See <a class="local">'Aldosteronomas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pheochromocytoma</strong> – We recommend surgery for all patients with biochemical documentation of pheochromocytoma. The preoperative management and surgical approach of patients with pheochromocytoma are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/142.html" rel="external">"Treatment of pheochromocytoma in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subclinical Cushing syndrome</strong> – We suggest surgical resection for patients with subclinical Cushing syndrome who are good surgical candidates and who have disorders potentially attributable to excess glucocorticoid secretion (eg, recent onset of hypertension, diabetes, obesity, and/or low bone mass) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Unilateral adrenal masses'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suspected metastatic disease</strong> – In a patient with a known primary malignancy elsewhere who has a newly discovered adrenal mass that has an imaging phenotype consistent with metastatic disease, performing a diagnostic CT-guided fine-needle aspiration (FNA) biopsy may be indicated, but <strong>only</strong> after excluding pheochromocytoma with biochemical testing. Adrenal biopsy is not needed if the patient is already known to have widespread metastatic disease. (See <a class="local">'Fine-needle aspiration biopsy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suspected carcinoma</strong> – We suggest excision of a tumor if the initial imaging phenotype is suspicious (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Unilateral adrenal masses'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Masses &gt;4 cm</strong> – In patients with adrenal masses greater than 4 cm in diameter, we consider surgical resection. However, the clinical scenario, imaging characteristics, and patient age frequently guide the management decisions in patients who have adrenal incidentalomas that fall on either side of the 4 cm diameter cutoff. (See <a class="local">'Size'</a> above and <a class="local">'Unilateral adrenal masses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenalectomy</strong> – The laparoscopic approach is used for most adrenal masses. In patients with known or suspected adrenal carcinoma, the laparoscopic approach should only be considered if the adrenal mass is &lt;10 cm and does not appear to be locally invasive. For all adrenal masses larger than 10 cm, including those masses with benign imaging phenotypes, we suggest an open adrenalectomy rather than a laparoscopic procedure (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Adrenalectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring when surgery not performed</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Repeat imaging</strong> – For incidentalomas with a benign appearance on imaging, we suggest a repeat imaging study at 12 months after initial discovery. The rationale is that many malignant lesions will grow in this interval, leading to earlier intervention. Whether to obtain additional images (eg, at 6, 12, and 24 months after initial discovery) and the type of image obtained (eg, CT, MRI, or ultrasound) should be guided by clinical judgment and imaging phenotype. The yield and cost-effectiveness of such a strategy are not known. (See <a class="local">'Monitoring when surgery not performed'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tumors with interim growth</strong> – We suggest removal of any tumor that enlarges by more than 1 cm in diameter during the follow-up period (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Monitoring when surgery not performed'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biochemical monitoring</strong> – We suggest that baseline DHEAS and an overnight DST be repeated annually for four years in cases where initial evaluation is negative, although the yield and cost effectiveness of such testing is also unknown. Autonomous function (glucocorticoid hypersecretion) not present at baseline may be detected at follow-up testing. (See <a class="local">'Monitoring when surgery not performed'</a> above.)</p><p></p><p class="headingAnchor" id="H1606607624"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p><p>The UpToDate editorial staff acknowledges Norman M Kaplan, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007; 356:601.</a></li><li><a class="nounderline abstract_t">Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 2003; 138:424.</a></li><li><a class="nounderline abstract_t">Herrera MF, Grant CS, van Heerden JA, et al. Incidentally discovered adrenal tumors: an institutional perspective. Surgery 1991; 110:1014.</a></li><li><a class="nounderline abstract_t">Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 2006; 29:298.</a></li><li><a class="nounderline abstract_t">Jing Y, Hu J, Luo R, et al. Prevalence and Characteristics of Adrenal Tumors in an Unselected Screening Population : A Cross-Sectional Study. Ann Intern Med 2022; 175:1383.</a></li><li><a class="nounderline abstract_t">Reimondo G, Castellano E, Grosso M, et al. Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol 2011; 164:851.</a></li><li><a class="nounderline abstract_t">Hedeland H, Ostberg G, Hökfelt B. On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes. Acta Med Scand 1968; 184:211.</a></li><li><a class="nounderline abstract_t">Angeli A, Osella G, Alì A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res 1997; 47:279.</a></li><li><a class="nounderline abstract_t">Barzon L, Scaroni C, Sonino N, et al. Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates. J Clin Endocrinol Metab 1998; 83:55.</a></li><li><a class="nounderline abstract_t">Kasperlik-Zeluska AA, Rosłonowska E, Słowinska-Srzednicka J, et al. Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol (Oxf) 1997; 46:29.</a></li><li><a class="nounderline abstract_t">Young WF Jr. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am 2000; 29:159.</a></li><li><a class="nounderline abstract_t">Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85:637.</a></li><li><a class="nounderline abstract_t">Cawood TJ, Hunt PJ, O'Shea D, et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol 2009; 161:513.</a></li><li><a class="nounderline abstract_t">Nieman LK. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab 2010; 95:4106.</a></li><li><a class="nounderline abstract_t">Wilson MP, Randhawa S, Bao B, et al. Impact of Size Thresholds on the Diagnosis of Incidental Adrenal Lesions: A Systematic Review and Meta-Analysis. J Am Coll Radiol 2023.</a></li><li><a class="nounderline abstract_t">Henley DJ, van Heerden JA, Grant CS, et al. Adrenal cortical carcinoma--a continuing challenge. Surgery 1983; 94:926.</a></li><li><a class="nounderline abstract_t">Iñiguez-Ariza NM, Kohlenberg JD, Delivanis DA, et al. Clinical, Biochemical, and Radiological Characteristics of a Single-Center Retrospective Cohort of 705 Large Adrenal Tumors. Mayo Clin Proc Innov Qual Outcomes 2018; 2:30.</a></li><li><a class="nounderline abstract_t">Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 2005; 90:871.</a></li><li><a class="nounderline abstract_t">Delivanis DA, Bancos I, Atwell TD, et al. Diagnostic performance of unenhanced computed tomography and 18 F-fluorodeoxyglucose positron emission tomography in indeterminate adrenal tumours. Clin Endocrinol (Oxf) 2018; 88:30.</a></li><li><a class="nounderline abstract_t">Korobkin M, Brodeur FJ, Francis IR, et al. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol 1998; 170:747.</a></li><li><a class="nounderline abstract_t">Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005; 234:479.</a></li><li><a class="nounderline abstract_t">Peña CS, Boland GW, Hahn PF, et al. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 2000; 217:798.</a></li><li><a class="nounderline abstract_t">Corwin MT, Badawy M, Caoili EM, et al. Incidental Adrenal Nodules in Patients Without Known Malignancy: Prevalence of Malignancy and Utility of Washout CT for Characterization-A Multiinstitutional Study. AJR Am J Roentgenol 2022; 219:804.</a></li><li><a class="nounderline abstract_t">Platzek I, Sieron D, Plodeck V, et al. Chemical shift imaging for evaluation of adrenal masses: a systematic review and meta-analysis. Eur Radiol 2019; 29:806.</a></li><li><a class="nounderline abstract_t">Groussin L, Bonardel G, Silvéra S, et al. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab 2009; 94:1713.</a></li><li><a class="nounderline abstract_t">Guerin C, Pattou F, Brunaud L, et al. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study. J Clin Endocrinol Metab 2017; 102:2465.</a></li><li><a class="nounderline abstract_t">Hennings J, Hellman P, Ahlström H, Sundin A. Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas. Eur J Radiol 2009; 69:314.</a></li><li><a class="nounderline abstract_t">Dunnick NR, Korobkin M, Francis I. Adrenal radiology: distinguishing benign from malignant adrenal masses. AJR Am J Roentgenol 1996; 167:861.</a></li><li><a class="nounderline abstract_t">Canu L, Van Hemert JAW, Kerstens MN, et al. CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. J Clin Endocrinol Metab 2019; 104:312.</a></li><li><a class="nounderline abstract_t">Mazzaglia PJ, Monchik JM. Limited value of adrenal biopsy in the evaluation of adrenal neoplasm: a decade of experience. Arch Surg 2009; 144:465.</a></li><li><a class="nounderline abstract_t">Cook DM, Loriaux DL. The incidental adrenal mass. Am J Med 1996; 101:88.</a></li><li><a class="nounderline abstract_t">Jhala NC, Jhala D, Eloubeidi MA, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy of the adrenal glands: analysis of 24 patients. Cancer 2004; 102:308.</a></li><li><a class="nounderline abstract_t">Lee JE, Evans DB, Hickey RC, et al. Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas. Surgery 1998; 124:1115.</a></li><li><a class="nounderline abstract_t">Welch TJ, Sheedy PF 2nd, Stephens DH, et al. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology 1994; 193:341.</a></li><li><a class="nounderline abstract_t">Arellano RS, Harisinghani MG, Gervais DA, et al. Image-guided percutaneous biopsy of the adrenal gland: review of indications, technique, and complications. Curr Probl Diagn Radiol 2003; 32:3.</a></li><li><a class="nounderline abstract_t">Vanderveen KA, Thompson SM, Callstrom MR, et al. Biopsy of pheochromocytomas and paragangliomas: potential for disaster. Surgery 2009; 146:1158.</a></li><li><a class="nounderline abstract_t">Casola G, Nicolet V, vanSonnenberg E, et al. Unsuspected pheochromocytoma: risk of blood-pressure alterations during percutaneous adrenal biopsy. Radiology 1986; 159:733.</a></li><li><a class="nounderline abstract_t">McCorkell SJ, Niles NL. Fine-needle aspiration of catecholamine-producing adrenal masses: a possibly fatal mistake. AJR Am J Roentgenol 1985; 145:113.</a></li><li><a class="nounderline abstract_t">Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002; 87:4872.</a></li><li><a class="nounderline abstract_t">Prete A, Subramanian A, Bancos I, et al. Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study. Ann Intern Med 2022; 175:325.</a></li><li><a class="nounderline abstract_t">Reznik Y, Lefebvre H, Rohmer V, et al. Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study. Clin Endocrinol (Oxf) 2004; 61:311.</a></li><li><a class="nounderline abstract_t">Hsiao HP, Kirschner LS, Bourdeau I, et al. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab 2009; 94:2930.</a></li><li><a class="nounderline abstract_t">Chiodini I, Morelli V, Masserini B, et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J Clin Endocrinol Metab 2009; 94:3207.</a></li><li><a class="nounderline abstract_t">Sereg M, Szappanos A, Toke J, et al. Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study. Eur J Endocrinol 2009; 160:647.</a></li><li><a class="nounderline abstract_t">Morelli V, Reimondo G, Giordano R, et al. Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab 2014; 99:827.</a></li><li><a class="nounderline abstract_t">Pelsma ICM, Fassnacht M, Tsagarakis S, et al. Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis. Eur J Endocrinol 2023; 189:S88.</a></li><li><a class="nounderline abstract_t">Morelli V, Eller-Vainicher C, Salcuni AS, et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. J Bone Miner Res 2011; 26:1816.</a></li><li><a class="nounderline abstract_t">Li D, Kaur RJ, Zhang CD, et al. Risk of bone fractures after the diagnosis of adrenal adenomas: a population-based cohort study. Eur J Endocrinol 2021; 184:597.</a></li><li><a class="nounderline abstract_t">Di Dalmazi G, Vicennati V, Pizzi C, et al. Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175:G1.</a></li><li><a class="nounderline abstract_t">Barrett C, van Uum SH, Lenders JW. Risk of catecholaminergic crisis following glucocorticoid administration in patients with an adrenal mass: a literature review. Clin Endocrinol (Oxf) 2015; 83:622.</a></li><li><a class="nounderline abstract_t">Rosas AL, Kasperlik-Zaluska AA, Papierska L, et al. Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature. Eur J Endocrinol 2008; 158:423.</a></li><li><a class="nounderline abstract_t">Dennedy MC, Annamalai AK, Prankerd-Smith O, et al. Low DHEAS: A Sensitive and Specific Test for the Detection of Subclinical Hypercortisolism in Adrenal Incidentalomas. J Clin Endocrinol Metab 2017; 102:786.</a></li><li><a class="nounderline abstract_t">Carafone LE, Zhang CD, Li D, et al. Diagnostic Accuracy of Dehydroepiandrosterone Sulfate and Corticotropin in Autonomous Cortisol Secretion. Biomedicines 2021; 9.</a></li><li><a class="nounderline abstract_t">Reincke M. Subclinical Cushing's syndrome. Endocrinol Metab Clin North Am 2000; 29:43.</a></li><li><a class="nounderline abstract_t">Tsagarakis S, Kokkoris P, Roboti C, et al. The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1998; 48:627.</a></li><li><a class="nounderline abstract_t">Young WF Jr, du Plessis H, Thompson GB, et al. The clinical conundrum of corticotropin-independent autonomous cortisol secretion in patients with bilateral adrenal masses. World J Surg 2008; 32:856.</a></li><li><a class="nounderline abstract_t">Ueland GÅ, Methlie P, Jøssang DE, et al. Adrenal Venous Sampling for Assessment of Autonomous Cortisol Secretion. J Clin Endocrinol Metab 2018; 103:4553.</a></li><li><a class="nounderline abstract_t">Johnson PC, Thompson SM, Adamo D, et al. Adrenal venous sampling for lateralization of cortisol hypersecretion in patients with bilateral adrenal masses. Clin Endocrinol (Oxf) 2023; 98:177.</a></li><li><a class="nounderline abstract_t">Motta-Ramirez GA, Remer EM, Herts BR, et al. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR Am J Roentgenol 2005; 185:684.</a></li><li><a class="nounderline abstract_t">Kopetschke R, Slisko M, Kilisli A, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol 2009; 161:355.</a></li><li><a class="nounderline abstract_t">Gruber LM, Hartman RP, Thompson GB, et al. Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery. J Clin Endocrinol Metab 2019; 104:1386.</a></li><li><a class="nounderline abstract_t">Yip L, Duh QY, Wachtel H, et al. American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary. JAMA Surg 2022; 157:870.</a></li><li><a class="nounderline abstract_t">Hurtado MD, Cortes T, Natt N, et al. Extensive clinical experience: Hypothalamic-pituitary-adrenal axis recovery after adrenalectomy for corticotropin-independent cortisol excess. Clin Endocrinol (Oxf) 2018; 89:721.</a></li><li><a class="nounderline abstract_t">Toniato A, Merante-Boschin I, Opocher G, et al. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg 2009; 249:388.</a></li><li><a class="nounderline abstract_t">Mantero F, Arnaldi G. Investigation protocol: adrenal enlargement. Clin Endocrinol (Oxf) 1999; 50:141.</a></li><li><a class="nounderline abstract_t">Emral R, Uysal AR, Asik M, et al. Prevalence of subclinical Cushing's syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical and surgical outcomes. Endocr J 2003; 50:399.</a></li><li><a class="nounderline abstract_t">Craig WD, Fanburg-Smith JC, Henry LR, et al. Fat-containing lesions of the retroperitoneum: radiologic-pathologic correlation. Radiographics 2009; 29:261.</a></li><li><a class="nounderline abstract_t">McGeoch SC, Olson S, Krukowski ZH, Bevan JS. Giant bilateral myelolipomas in a man with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2012; 97:343.</a></li><li><a class="nounderline abstract_t">Liao CH, Lai MK, Li HY, et al. Laparoscopic adrenalectomy using needlescopic instruments for adrenal tumors less than 5cm in 112 cases. Eur Urol 2008; 54:640.</a></li><li><a class="nounderline abstract_t">Thompson GB, Grant CS, van Heerden JA, et al. Laparoscopic versus open posterior adrenalectomy: a case-control study of 100 patients. Surgery 1997; 122:1132.</a></li><li><a class="nounderline abstract_t">Gonzalez RJ, Shapiro S, Sarlis N, et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 2005; 138:1078.</a></li><li><a class="nounderline abstract_t">Saunders BD, Doherty GM. Laparoscopic adrenalectomy for malignant disease. Lancet Oncol 2004; 5:718.</a></li><li><a class="nounderline abstract_t">Porpiglia F, Fiori C, Daffara F, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 2010; 57:873.</a></li><li><a class="nounderline abstract_t">Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 2010; 58:609.</a></li><li><a class="nounderline abstract_t">Leboulleux S, Deandreis D, Al Ghuzlan A, et al. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol 2010; 162:1147.</a></li><li><a class="nounderline abstract_t">Miller BS, Ammori JB, Gauger PG, et al. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg 2010; 34:1380.</a></li><li><a class="nounderline abstract_t">Libè R, Dall'Asta C, Barbetta L, et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol 2002; 147:489.</a></li><li><a class="nounderline abstract_t">Bülow B, Jansson S, Juhlin C, et al. Adrenal incidentaloma - follow-up results from a Swedish prospective study. Eur J Endocrinol 2006; 154:419.</a></li><li><a class="nounderline abstract_t">Barzon L, Scaroni C, Sonino N, et al. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 1999; 84:520.</a></li></ol></div><div id="topicVersionRevision">Topic 153 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17287480" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice. The incidentally discovered adrenal mass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614096" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of the clinically inapparent adrenal mass ("incidentaloma").</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1745970" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidentally discovered adrenal tumors: an institutional perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16699294" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of adrenal incidentaloma in a contemporary computerized tomography series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36095315" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence and Characteristics of Adrenal Tumors in an Unselected Screening Population : A Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31900474" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21471169" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : AME position statement on adrenal incidentaloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5703975" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9167965" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9435416" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9059555" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10732270" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10690869" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19439510" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823463" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Approach to the patient with an adrenal incidentaloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37634790" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Impact of Size Thresholds on the Diagnosis of Incidental Adrenal Lesions: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6648806" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Adrenal cortical carcinoma--a continuing challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30225430" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical, Biochemical, and Radiological Characteristics of a Single-Center Retrospective Cohort of 705 Large Adrenal Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15572420" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28815667" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diagnostic performance of unenhanced computed tomography and 18 F-fluorodeoxyglucose positron emission tomography in indeterminate adrenal tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9490968" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : CT time-attenuation washout curves of adrenal adenomas and nonadenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15671003" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11110946" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35731098" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Incidental Adrenal Nodules in Patients Without Known Malignancy: Prevalence of Malignancy and Utility of Washout CT for Characterization-A Multiinstitutional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30014203" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Chemical shift imaging for evaluation of adrenal masses: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19190108" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28431167" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18082990" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8819372" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Adrenal radiology: distinguishing benign from malignant adrenal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383267" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451490" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Limited value of adrenal biopsy in the evaluation of adrenal neoplasm: a decade of experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8686720" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The incidental adrenal mass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15376200" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Endoscopic ultrasound-guided fine-needle aspiration biopsy of the adrenal glands: analysis of 24 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854592" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7972740" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Percutaneous adrenal biopsy: review of a 10-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12574782" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Image-guided percutaneous biopsy of the adrenal gland: review of indications, technique, and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19958944" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Biopsy of pheochromocytomas and paragangliomas: potential for disaster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3517958" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Unsuspected pheochromocytoma: risk of blood-pressure alterations during percutaneous adrenal biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3873829" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fine-needle aspiration of catecholamine-producing adrenal masses: a possibly fatal mistake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12414841" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34978855" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355446" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19509103" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19549741" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19174533" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24423350" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term follow-up in adrenal incidentalomas: an Italian multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37801655" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21472775" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33606665" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Risk of bone fractures after the diagnosis of adrenal adenomas: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32413902" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27390021" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25940577" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Risk of catecholaminergic crisis following glucocorticoid administration in patients with an adrenal mass: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299478" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27797672" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Low DHEAS: A Sensitive and Specific Test for the Detection of Subclinical Hypercortisolism in Adrenal Incidentalomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34203283" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Diagnostic Accuracy of Dehydroepiandrosterone Sulfate and Corticotropin in Autonomous Cortisol Secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10732263" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Subclinical Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9666875" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18074172" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The clinical conundrum of corticotropin-independent autonomous cortisol secretion in patients with bilateral adrenal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30137397" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Adrenal Venous Sampling for Assessment of Autonomous Cortisol Secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36263687" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Adrenal venous sampling for lateralization of cortisol hypersecretion in patients with bilateral adrenal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120918" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19497985" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30462226" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35976622" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29968420" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Extensive clinical experience: Hypothalamic-pituitary-adrenal axis recovery after adrenalectomy for corticotropin-independent cortisol excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19247023" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10396353" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Investigation protocol: adrenal enlargement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14599113" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prevalence of subclinical Cushing's syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical and surgical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19168848" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Fat-containing lesions of the retroperitoneum: radiologic-pathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22238394" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Giant bilateral myelolipomas in a man with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18164803" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Laparoscopic adrenalectomy using needlescopic instruments for adrenal tumors less than 5cm in 112 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9426429" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Laparoscopic versus open posterior adrenalectomy: a case-control study of 100 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16360394" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Laparoscopic resection of adrenal cortical carcinoma: a cautionary note.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15581542" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Laparoscopic adrenalectomy for malignant disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20137850" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20580485" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20348273" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20372905" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370111" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Long-term follow-up study of patients with adrenal incidentalomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16498055" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Adrenal incidentaloma - follow-up results from a Swedish prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022410" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Risk factors and long-term follow-up of adrenal incidentalomas.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
